Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Self-reactive antibodies known as ANCAs, which bind to and excessively activate neutrophils, are the cause behind this inflammation. This immune system malfunction is caused by hereditary and environmental factors. ANCA vasculitis can result in a variety of symptoms depending on the organ or body part affected. For instance, if the skin's blood vessels are harmed, a rash may result. Blood and protein leakage into the urine as well as kidney damage can result from problems with the blood vessels in the kidney. There are three main types of ANCA vasculitis, microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Currently, there is no cure for the disease and treatments are available to manage the condition. Patients normally undergo two phases of treatment, one designed to induce the remission of symptoms (induction treatment), and a second phase meant to keep patients in remission for as long as possible (maintenance treatment).

Market Dynamics

Key players in market are focused on carrying out research and development activities and demonstrating the results of the studies at various medical conferences, which is expected to drive the market growth over the forecast period. For instance, in May 2022, ChemoCentryx, Inc., a biopharmaceutical company, announced upcoming presentations at three key medical conferences that would highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of tavneos (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. The three conferences were ATS 2022 (American Thoracic Society), May 15-17, 2022, San Francisco, ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, 2022, Washington, and 59th ERA Conference (European Renal Association), May 19-22, 2022, Paris, France/Virtual

Key features of the study:

• This report provides in-depth analysis of the global ANCA vasculitis drug market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ANCA vasculitis drug market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global ANCA vasculitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ANCA vasculitis drug market

Detailed Segmentation:

• Global ANCA Vasculitis Drug Market, By Type:
  • Granulomatosis with Polyangiitis (GPA) 
  • Microscopic Polyangiitis (MPA)  
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA) 
  • Renal-limited Vasculitis
• Global ANCA Vasculitis Drug Market, By Drug Type:
  • Glucocorticoids
  • Cyclophosphamide
  • Rituximab
  • Methotrexate
  • Mycophenolate mofetil
  • Azathioprine
  • Mepolizumab
  • Avacopan 
  • Others
• Global ANCA Vasculitis Drug Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies 
  • Online Pharmacies 
• Global ANCA Vasculitis Drug Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe  
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • ChemoCentryx, Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Vifor Pharma
  • GlaxoSmithKline plc
  • Amgen
  • Genentech, Inc.
  • Pfizer Inc.
  • Biogen
  • InflaRx GmbH
  • AstraZeneca

 “*” marked represents similar segmentation in other categories in the respective section.